← Eichor
Study identifier: NCT07537426 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Efficacy of Intradermal Acupuncture for Ocular Surface Diseases After Intractable Facial Paralysis

Condition: Facial Paralysis, Peripheral · Bell's Palsy · Ocular Surface Disease  ·  Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University

PhaseNA
Planned participants78
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The purpose of this study is to explore the clinical efficacy of intradermal acupuncture in the treatment of ocular surface diseases after Intractable Facial Paralysis, and to seek effective and convenient treatment for ocular surface diseases after intractable peripheral facial paralysis. The main question it aims to answer is : Will the intradermal acupuncture intervention effectively reduce the OSDI score ? The researchers compared the intradermal acupuncture with the placebo-needle to observe whether the intradermal acupuncture could better improve the symptoms.

This description comes directly from the study's public registry record.

Talk to the study team

Binyan Yu Binyan Yu  ·  13758271294  ·  20103034@zcmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Zhejiang University of Traditional Chinese MedicineHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07537426